Palatin Technologies, Inc.
(NYSE Amex Equities : PTN)

( )
PTN After-Hours: () as of PM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Interested in Gold Updates?
Receive the latest updates on the gold and silver markets.
100% secure: your email is never shared, and you may opt out at any time.
Loading PTN News...
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
GILDGilead Sciences, Inc.
-0.66%68.831.0%$926.55m
AMGNAmgen Inc.
-0.31%172.610.8%$655.47m
BIIBBiogen Inc.
0.25%287.630.9%$526.94m
CELGCelgene Corporation
-0.14%119.271.0%$480.99m
REGNRegeneron Pharmaceuticals, Inc.
-0.37%370.221.9%$341.26m
ALXNAlexion Pharmaceuticals, Inc.
0.72%130.832.0%$299.85m
TSROTESARO, Inc.
-0.17%189.9415.3%$195.91m
INCYIncyte Corporation
-0.82%121.362.3%$163.54m
ILMNIllumina, Inc.
0.09%162.303.9%$144.45m
VRTXVertex Pharmaceuticals Incorporated
-0.88%85.792.6%$139.38m
EXELExelixis, Inc.
-2.12%22.625.5%$127.92m
CLVSClovis Oncology, Inc.
-2.86%61.1916.4%$127.65m
AAgilent Technologies, Inc.
-0.04%51.331.7%$116.31m
ACADACADIA Pharmaceuticals Inc.
-0.15%39.1419.0%$93.49m
BMRNBioMarin Pharmaceutical Inc.
-0.50%89.794.0%$90.43m

Company Profile

Palatin Technologies, Inc. is a biopharmaceutical company which develops targeted, receptor-specific peptide therapeutics for the treatment of diseases with significant unmet medical need and commercial potential. Its programs are based on molecules that modulate the activity of the melanocortin and natriuretic peptide receptor systems. Its primary product in development is bremelanotide for the treatment of female sexual dysfunction. It is also developing an inhalation formulation of peptide mimetic natriuretic peptide receptor A-agonist, for treatment of cardiovascular and pulmonary indications. The company was founded by Carl Spana and John K. A. Prendergast on November 21, 1986 and is headquartered in Cranbury, NJ.